{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ecsedi M"],"funding":["Fred Hutchinson Cancer Research Center","MPN Research Foundation","NCI NIH HHS","NIH","Damon Runyon Cancer Research Foundation"],"pagination":["48-56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7770096"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(1)"],"pubmed_abstract":["Adoptively transferred T cell receptor (TCR)-transgenic T cells (TCR-T cells) are not restricted by cell surface expression of their targets and are therefore poised to become a main pillar of cellular cancer immunotherapies. Addressing clinical and laboratory data, we discuss emerging features for the efficient deployment of novel TCR-T therapies, such as selection of ideal TCRs targeting validated epitopes with well-characterized cancer cell expression and processing, enhancing TCR-T effector function, trafficking, expansion, persistence, and memory formation by strategic selection of substrate cells, and gene-engineering with synthetic co-stimulatory circuits. Overall, a better understanding of the relevant mechanisms of action and resistance will help prioritize the vast array of potential TCR-T optimizations for future clinical products."],"journal":["Trends in cancer"],"pubmed_title":["The Anticancer Potential of T Cell Receptor-Engineered T Cells."],"pmcid":["PMC7770096"],"funding_grant_id":["CA18029-39","P01 CA225517","P01 CA018029","CA225517-01"],"pubmed_authors":["McAfee MS","Ecsedi M","Chapuis AG"],"additional_accession":[]},"is_claimable":false,"name":"The Anticancer Potential of T Cell Receptor-Engineered T Cells.","description":"Adoptively transferred T cell receptor (TCR)-transgenic T cells (TCR-T cells) are not restricted by cell surface expression of their targets and are therefore poised to become a main pillar of cellular cancer immunotherapies. Addressing clinical and laboratory data, we discuss emerging features for the efficient deployment of novel TCR-T therapies, such as selection of ideal TCRs targeting validated epitopes with well-characterized cancer cell expression and processing, enhancing TCR-T effector function, trafficking, expansion, persistence, and memory formation by strategic selection of substrate cells, and gene-engineering with synthetic co-stimulatory circuits. Overall, a better understanding of the relevant mechanisms of action and resistance will help prioritize the vast array of potential TCR-T optimizations for future clinical products.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-04T13:12:18.154Z","creation":"2022-02-11T14:02:12.52Z"},"accession":"S-EPMC7770096","cross_references":{"pubmed":["32988787"],"doi":["10.1016/j.trecan.2020.09.002"]}}